Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belumosudil in diffuse cutaneous systemic sclerosis
NCT03919799Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Jun 2019
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of belumosudil in diffuse cutaneous systemic sclerosis (dcSSc) (3 arms), sponsored by Sanofi. Primary endpoint: Combined Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS) Score >= 60% at 24 weeks. Started Jun 2019; status: terminated.
02
Drugs
belumosudil
03
Conditions
diffuse cutaneous systemic sclerosis (dcSSc)
Beyond the preview
Go deeper on NCT03919799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03919799.